Sex/gender disparities in dolutegravir uptake persist despite WHO OK for women of reproductive age with HIV

An observational study found that gender/sex disparities in the use of dolutegravir-containing antiretroviral therapy (ART) persist despite World Health Organization (WHO) endorsement for its use among women with HIV of reproductive age. The study authors say this disparity greatly limits the population health benefits of dolutegravir for a substantial number of women with HIV around the world. Their findings are published in Annals of Internal Medicine.

source https://medicalxpress.com/news/2021-11-sexgender-disparities-dolutegravir-uptake-persist.html